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a b s t r a c t
Despite recent advances in precision medicine, many molecular-based antineoplastic agents do not
potentiate sustainable long term remissions, warranting the investigation of novel therapeutic strate-
gies. Heat shock protein 90 (Hsp90) is a molecular chaperone that not only has oncogenic properties,
but also has distinct expression proﬁles in malignant and normal cells, providing a rational strategy
to attain preferential damage. Prior attempts to target Hsp90 with natural product-based compounds
have been hampered by their associated off target toxicities, suggesting that novel, fully synthetic
inhibitors may be required to achieve the speciﬁcity necessary for therapeutic efﬁcacy. Therefore, this
review highlights the antineoplastic potential of PU-H71 (8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]-9-
[3-(propan-2-ylamino)propyl]purin-6-amine), a novel purine based analog that has shown efﬁcacy in
many preclinical models of malignancy, and is now under clinical examination. In addition, the review
suggests potential concomitant therapeutic approaches that may be particularly beneﬁcial to molecular-
based, as well as traditional cytotoxic cancer chemotherapy.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
The world of antineoplastic drug discovery is changing. Tra-
ditionally, agents designed for cancer chemotherapy rely on the
principal that malignant cells have higher proliferation rates than
normal cells, enabling the selective poisoning of malignant tissue
with agents that disrupt vital components of the cell cycle. Specif-
ically, these traditional antineoplastic agents target either nucleic
acids and proteins involved in DNA synthesis and transcription, or
microtubules responsible for chromosome congression and proper
segregation of chromosomes during anaphase [1]. While effective
against several hematological malignancies and solid tumors, tra-
ditional chemotherapeutic agents are inherently limited by their
less than ideal toxicityproﬁles, producing signiﬁcantdeleteriousoff
target effects in patients that limit dosing schedules. Further, many
cancers are refractory or eventually develop resistance to tradi-
tional cytotoxic agents, thereby potentiating drug resistant tumors
that portend a very poor prognosis.
In recent years, the commendable progress inmolecular biology
has enabled investigators to probe deregulated signaling path-
ways and oncoproteins that are imperative for carcinogenesis. This
has launched the introduction of precision medicine in cancer
chemotherapy inwhichcliniciansnowhave the capability of select-
ingoptimal therapiesbasedon thegenetic andphenotypicproﬁleof
the patient’s malignancy in addition to traditional broad spanning
cytotoxic antineoplastic intervention. Novel targeted approaches,
suchashormonal therapy,monoclonal antibodies (mABs) andasso-
ciated immunoconjugates, and small molecule kinase inhibitors
have given clinicians an unprecedented ability to discriminate
between neoplastic and normal tissue. Nevertheless, these agents
suffer from many of the same pitfalls associated with traditional
cytotoxic chemotherapy. Hormonal therapy is limited in the scope
of tumors perturbed by such intervention, and such protocols have
a low, but notable risk of potentiating other malignancies in addi-
tion to inducing an initial surge in tumor growth [2,3]. In the case
of immunotherapy, tumors are not homogeneous in their cell sur-
face protein expression, and it is possible that some cells lack the
required epitope, or inadvertently shed the required antigen if it
is unnecessary for cell survival [4–7]. Kinase inhibitors enable the
clinician to select forpatientmalignancies that relyonspeciﬁcaber-
rantly expressedpathways, but are often toxic tonormal cells based
on the requirement of these signals for homeostatic functions [8,9].
Although the amount of progress cancer chemotherapy has
made in recent years is noteworthy, there is an apparent need for
chemotherapeutic agents that work by mechanisms not currently
approved for clinical use. Recent work has implicated molecular
chaperones, ubiquitously expressed proteins vital to the formation
of certain macromolecular structures, to be a particularly intrigu-
ing target of interest. Molecular chaperones are members of a
unique class of proteins that constitute the chaperome, an inter-
connected network of molecular chaperones, co-chaperones, and
folding enzymes encoded by as many as 169 genes that help main-
tain cell stability by regulating proteome machinery required for
a vast array of housekeeping activities [10]. The ubiquitous nature
of chaperones initially suggested that the chaperome was of lit-
tle interest to oncology as such proteins are highly expressed in
both normal and malignant cells. However, there exist inherent
differences in the expression proﬁle of chaperones under normal
conditions and those inducedbyoncogenic stress [10–12], enabling
the targeted inhibition of proteins vital for malignant tissue.
A particular molecular chaperone of interest is heat shock
protein 90 (Hsp90), which has been shown to support aberrant
expression of key oncoproteins such as ALK (anaplastic lymphoma
kinase), BCR-ABL (break point cluster-Abelson tyrosine kinase)
BRAF (serine/threonine-protein kinase B-Raf), CDK4 (cyclin-
dependent kinase 4), CRAF (serine/threonine-protein kinaseC-Raf),
HER2 (human epidermal growth factor receptor 2), JAK2 (Janus
kinase 2), KIT (Mast/stem cell growth factor receptor, proto-
oncogene c-Kit) MET (mesenchymal epithelial transition factor),
and STK33 (serine/threonine kinase 33) [13–17]. Initial attempts
to target Hsp90 with inhibitors that resemble the structure of
the natural products geldanamycin and radicicol indicated that
successful targeting of the chaperone could yield therapeutic ben-
eﬁt at the clinical level, but such compounds are plagued by
unfavorable toxicity proﬁles that limit achievable doses [18,19].
Consequently, these lower concentrations are unable to sustain
consistent antineoplastic activity, and have limited clinical utility.
Nevertheless, structure–activity studies have enabled the design
of novel purine-based inhibitors [20–23] that have demonstrated
notable speciﬁcity toward oncogenicHsp90. Themost promising of
these agents, PU-H71, is currently under clinical investigation, and
will bediscussed at length todemonstratehowrational drugdesign
can potentiate the development of chemotherapeutic agents that
are highly potent and selective toward malignant tissue.
2. Structure and function of heat shock protein 90
Hsp90 refers to a subgroup of molecular chaperones that fold
client proteins to their active conformation through their ATPase
activity, and have a characteristic Bergerat fold (unique struc-
tural ATP-binding domain) near the N-terminus. There are four
different paralogues of Hsp90, each of which has a distinct cellu-
lar location; Hsp90 and Hsp90 in the cytoplasm, gp96 (Grp94,
ERp99, or endoplasmin) in the endoplasmic reticulum, and Trap-
1 in the mitochondria [22,23]. Hsp90 substrates are regulated by
the N-terminal ATPase domain, which binds and hydrolyses ATP to
mediate association/dissociation cycles between Hsp90 and client
proteins [24,25]. This ATPase activity produces several confor-
mations of Hsp90 based on ATP binding status and whether the
nucleotide has been hydrolyzed (Fig. 1). The activity of Hsp90 is
further regulated by co-chaperones which aid in the conversion
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Fig. 1. Three conformations of heat shock protein 90 and the quaternary complex of heat shock protein 70, heat shock protein 90, and Hsp-organizing protein. Three possible
tertiary structures of Hsp90 are known to exist; apo (open), ADP bound, and ATP bound. In addition, a three dimensional rendering of the Hsp90:HOP:Hsp70 quaternary
complex is shown, depicting the atomic structures of Hsp90, the HOP domains TPR1, DP1, the TPR2A-TPR2B module and DP2, the Hsp70NBD and Hsp70SBD domains.
Source: Images were adapted from [27] and [28].
between ATP- and ADP-bound states and modulate the formation
of client-speciﬁc complexes. Speciﬁcally, its 70kDa co-chaperone
Hsp70 initiates the association of the client protein with Hsp90
through a bridging protein called Hsp-organizing protein (HOP)
(Fig. 1) [26–28]. Together, these proteins ensure proper folding of
essential proteins vital for both normal and carcinogenic processes.
Traditionally, Hsp90 inhibitorswork by binding the ATP domain
of the protein, thereby preventing proper folding of client pro-
teins. Since many oncoproteins are also clients of Hsp90 [13–17],
these macromolecules are targeted for destruction, often via the
ubiquitin/proteasome system [12]. Therefore, malignant growths
are starved of proteins vital for maintaining the malignant pheno-
type, eventually initiating apoptotic mechanisms. Although Hsp90
is ubiquitously expressed in both normal and neoplastic cells,
potential therapeutic intervention is possible due to its distinctive
activation in normal and stressed environments. As demonstrated
in multiple malignant cell lines, Hsp90 typically forms complexes
with co-chaperones that have a high afﬁnity for ATP/ADP and
other ligands of this binding pocket (including ATPase inhibitors),
whereas in normal tissues, Hsp90 exists primarily in an uncom-
plexed, low afﬁnity state [29,30]. The shift in equilibrium between
latent and activated states is thought to be dictated by the amount
of stresses incurred by the cell, which is increased in transformed
counterparts due to the effects of mutated and deregulated pro-
teins, hypoxia, and a low nutrient concentration environment [21].
In addition, it has been elucidated that cancer cells do not have a
uniformcompositionofhighafﬁnityHsp90.Rather, theproteins are
a composite of housekeeping Hsp90s (with low afﬁnity to particu-
lar smallmolecule inhibitors that are very similar toHsp90 found in
normal cells) and oncogenic Hsp90s [31]. These epigenetically dis-
tinctHsp90 forms are similar to the onesusedduring cellular stress,
but are enriched or expanded in cancer cells. Consequently, malig-
nancies use the elevated levels of stress Hsp90s to maintain altered
proteins and protein expression levels vital for cancer pathology
[31]. The therapeutic activity of Hsp90 inhibitors lies in their abil-
ity to preferentially interact with oncogenic Hsp90s, acting on
housekeepingHsp90sonly athigheror at saturating concentrations
[10]. To summarize, neoplastic cells contain a complex mixture
of Hsp90s. A majority of these chaperones perform housekeeping
functions similarly to non-stressed, normal cells, but a notable frac-
tion buffers the proteomealtered in the process of oncogenic stress.
These stress-induced and stress-associated Hsp90s are proposed
to be epigenetically and thermodynamically distinct from house-
keeping Hsp90s, thereby providing a rationale for their selective
targeting by small molecule inhibitors.
3. Initial attempts to target heat shock protein 90 using
semisynthetic derivatives of natural products
AlthoughHsp90 is a relatively novel therapeutic target in oncol-
ogy, there have already been numerous clinical studies evaluating
the potential of semisynthetic derivatives based on the structure of
natural products geldanamycinand radicicol.Geldanamycin (Fig. 2)
is a benzoquinone ansamycin antibiotic originally isolated in 1970
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Fig. 2. Natural product Hsp90 inhibitors. Important functional moieties are highlighted with color coded outlines; blue (benzoquinone moiety), red (carbamate moiety),
and green (resorcinol moiety). The numbering system for each compound is highlighted in blue. Molecular weights for geldanamycin and radicicol are indicated underneath
their corresponding molecular structures. (For interpretation of the references to color in this legend, the reader is referred to the web version of the article.)
from Streptomyces hygroscopicus [32], the same bacterium that
produces the mTOR (mechanistic target of rapamycin) inhibitor
rapamycin. Geldanamycin binds the ATP binding pocket of Hsp90
by positioning the macrocyclic ansa ring and carbamate moiety
toward the bottom of the pocket, while the benzoquinone ring
is oriented toward the top of the pocket [33]. Once appropriately
positioned, geldanamycin forms hydrogen bonds within the ATP
bindingpocket, including interactionsbetween themacrocycle car-
bamate carbonyl and a key aspartate residue at the bottom of
the pocket, thereby mimicking the actions of ATP [33]. While this
activity potently inhibits Hsp90 function, the antibiotic was never
investigated at the clinical level due to its poor in vivo stability
and toxicity stemming from the benzoquinone moiety that under-
goes reductive metabolism by nicotinamide adenine dinucleotide
phosphate (NADPH): quinone oxidoreductase (NQ01) before it acts
against Hsp90 [34–36].
Nevertheless, geldanamycin provided an important scaffold
to base semisynthetic derivatives with improved solubility and
a reduced toxicity proﬁle that could be assessed at the clini-
cal level. Replacement of the non-essential C-17 methoxy group
of geldanamycin via substitution with various amines provided
many semisynthetic derivatives, one of which was 17-AAG (17-N-
allylamino-17-demethoxygeldanamycin/tanespimycin), the ﬁrst
Hsp90 inhibitor to be clinically evaluated. 17-AAG retains the
anti-Hsp90 activity observed with its natural product counter-
part, but has an improved toxicity proﬁle. Nevertheless, 17-AAG
produced disappointing clinical results, as the agent still had an
unacceptable pharmaceutical and toxicity proﬁle, even after the
development of an improved formulation [37,38]. In addition, the
therapeutic indexof17-AAG is fundamentally limitedby thebenzo-
quinone moiety that causes marked hepatotoxicity and potentially
may constitute a mechanism of drug resistance in patients with
a mutation in NQ01, the enzyme that actuates its anticancer
activity [39].
Despite these shortcomings, investigators have pressed on
with the development of geldanamycin-based Hsp90 inhibitors,
leading to the development of 17-DMAG (17-desmethoxy-17-
N,N-dimethylaminoethylaminogeldanamycin/alvespimycin). To
improve aqueous solubility, 17-DMAG contains an ionizable N,N-
dimethylethylamine group instead of a methoxy group at C-17.
This slight alteration tremendously improves its hydrophilicity
and oral bioavailability [40,41], while still retaining equal, if
not superior, antitumor activity in comparison to 17-AAG [39].
Although 17-DMAG still potentiates notable toxicity in patients
(liver, lung, ocular and cardiac toxicities in addition to common
side effects such as diarrhea, fatigue and nausea [42–45]) the
agent does appear to be tolerable, and has shown increased activ-
ity when combined with the HER2-targeting mAB trastuzumab
[46]. In addition to 17-DMAG, IPI-504 (retaspimycin) is another
geldanamycin-based Hsp90 inhibitor that has shown potential at
the clinical level. IPI-504 is a reduced quinone form of 17-AAG,
and has higher solubility than either 17-AAG or 17-DMAG [39].
Further, since IPI-504 lacks the benzoquinone moiety, it does not
potentiate hepatotoxicity as much as its related congeners [39].
IPI-504 has shown notable activity against EML4-ALK (echino-
derm microtubule-associated protein-like 4-anaplastic lymphoma
kinase) positive non-small cell lung carcinoma (NSCLC) [46,47],
and HER2 positive breast carcinoma [48,49].
Radicicol-based Hsp90 inhibitors have also been evaluated at
the clinical level. Initially isolated in 1953 from the fungusMonocil-
lium nordinii [50], radicicol (Fig. 2) is a 14-member macrolide that
demonstrates potent Hsp90 activity due to a resorcinol moiety,
which binds the same aspartate residue as geldanamycin via its 3-
hydroxyl group.However, radicicol is also associatedwith the same
issues of low solubility and therapeutic index in addition to being
unstable in plasma [39,51], thereby requiring the intervention
of medicinal chemistry. Unlike geldanamycin-based compounds,
those that employ the resorcinol moiety are highly heterogeneous
in structure, and are only loosely related by their pharmacophore.
The resorcinol core of radicicol is found in a number of agents
that have been clinically evaluated, including NVP-AUY922, AT-
13387, STA-9090 (ganetespib), and KW-2478. Out of these agents,
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STA-9090 has so far made the most progress in research and
development, being evaluated in over 25 clinical studies, includ-
ing an ongoing Phase III trial [39]. STA-9090 is a novel resorcinolic
triazolone Hsp90 inhibitor that potently inhibits cell proliferation
and induces apoptosis in a variety of cancer cell lines resistant to
tyrosine kinase inhibitors (TKIs) and 17-AAG in vitro and in vivo
[52,17,53]. Theagenthasnotable, but likelymanageable side effects
including diarrhea, hyperbilirubinemia/hyponatremia, QTc prolon-
gation, and elevated transaminases, a potential indicator of liver
damage [54–57]. STA-9090appears to showclinical efﬁcacy against
malignancies positive for known Hsp90 clients, including EML4-
ALK positive NSCLC [58], HER2 positive breast carcinoma [59], and
KIT positive gastrointestinal stromal tumor (GIST) [60,61]. Since
Hsp90 inhibition is known to induce G2/M arrest [61,62], STA-9090
has beenused in combinationwithmitotic inhibitors at the preclin-
ical and clinical level, with enhanced cytotoxicity being observed
[39,63–65].
4. Designing a rational inhibitor of heat shock protein 90 to
improve upon nature’s solutions
Although there is a considerable diversity of Hsp90 inhibitors
that have been, or are currently being clinically evaluated, none of
these drug candidates are anywhere near approval by the U.S. Food
and Drug Administration (FDA), or other pharmaceutical regulat-
ing bodies. While some of the more recent Hsp90 inhibitors show
some clinical potential, the original agents of this drug class suf-
fered from notable off target effects, limiting the concentrations
that could safely be administered in patients. Many of these agents
are natural product-based compounds that happen to potently
inhibitHsp90 function, butwerenot speciﬁcally designed for inhib-
iting the oncogenic functions of the protein. Therefore, medicinal
chemists have sought to design fully synthetic Hsp90 inhibitors
that retain or exceed the activity of natural products, but demon-
strate higher speciﬁcity, greatly increasing the therapeutic index.
One suchdrugclass, purine-basedHsp90 inhibitors,wasdiscovered
by Chiosis and colleagues at the Memorial Sloan Kettering Cancer
Center (New York, NY, USA). As will be discussed, the most promis-
ing of these fully synthetic inhibitors, PU-H71, is potently cytotoxic
against vital oncoproteins, including those not previously charac-
terized as Hsp90 clients, while demonstrating notable preferential
activity against malignant tissue.
4.1. Structure–activity examinations reveal a purine-based
approach to inhibit heat shock protein 90
Around the turn of this century, it was apparent that Hsp90
was a potential antineoplastic target that was in desperate need
of inhibitors with improved therapeutic indices. Therefore, Chio-
sis and colleagues set about designing novel compounds through
structure–activity rationale. To synthesize compounds speciﬁc to
Hsp90, Chiosis et al. meticulously examined the Hsp90 ATP bind-
ing pocket, and realized that an agent would have to satisfy several
hydrophilic and lipophilic interactions at this site, while retain-
ing higher afﬁnity for the pocket than ADP [20]. The laboratory
chose to examine purine-based congeners because it was known
that more than 10% of the proteins encoded by the yeast genome
depend on purine-containing ligands for their function, suggesting
that diverse purine librarieswould yield bioactive compoundswith
good solubility, an issue that many of the initial Hsp90 inhibitors
failed to address. They then reasoned that protein selectively
would be feasible by appropriate alterations to the carbon skeleton,
which is relatively straightforward for purine-based compounds,
especially since the size and nature of the purine N-9-alkyl can
be readily modiﬁed. Further, a purine-based compound could be
oriented in the same spatial orientation as the adenine ring of ATP
in the nucleotide pocket of Hsp90.
By understanding the differences between the ATP pocket of
Hsp90, and homologous pockets in other proteins, Chiosis et al.
designed PU3 (9-butyl-8(3,4,5-trimethoxy-benzyl)-9H-purin-6-
ylamine; Fig. 3A), the ﬁrst fully synthetic pan-Hsp90 inhibitor [20].
Although PU3 was shown to preferentially damage breast car-
cinoma cells by inhibiting oncogenic Hsp90 function and even
inducing differentiation in MCF7 human breast carcinoma cells,
PU3 was not as potent as 17-AAG. Nevertheless, the study demon-
strated that fully synthetic Hsp90 inhibitors could be rationally
developed, suggesting that the activity of purine-based compounds
couldbe improved throughappropriate structural alterations. Later
structure–activity relationship analyses revealed that PU3 con-
forms to the ADP binding site of Hsp90 and , with residues
104–111 adopting a helical conformation to provide space for the
trimethoxy phenyl moiety to bind. Further, the purine ring mim-
ics the adenine of ADP/ATP, occupying the same position as is
seen with the nucleotide [66]. Chiosis and colleagues later went
on to optimize this novel class of compounds, resulting in con-
geners bearing a thioether bridge to connect the purine nucleus
to substituted phenyl rings. These new compounds retain the pri-
mary amine attached to the purine core and contain an aryl moiety
separated by ∼5 A˚ to augment binding to Hsp90 [18]. Of note, PU-
H58 (8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-(4-pentyn-1-
yl)-9H-purin-6-amine) demonstrated much higher potency than
the original compound, and PU24F-Cl (2-ﬂuoro-9-pent-4-ynyl-8-
(2-chloro-3,4,5-trimethoxy-benzyl)-9H-purin-6-ylamine) had an
afﬁnity for the N-terminus of Hsp90 that was 30 times greater than
PU3 [67,68].
In addition, Biogen idec demonstrated that the presence of an
amino group on the C-2 position of the purine nucleus enables
multiple possibilities for hydrogen bonding, thereby allowing an
aromatic group to be attached at N-9 rather than the C-8 of
the purine. This structural modiﬁcation resulted in the produc-
tion of BIIB021 (6-chloro-9-((4-methoxy-3,5-dimethylpyridin-2-
yl)methyl)-9H-purin-2-amine), which entered clinical trials in
2005 [18]. BIIB021 has several associated off target effects,
including dose limiting toxicities of syncope and dizziness, and
other grade 3 or 4 toxicities such as fatigue, hyponatremia and
hypoglycemia. Nevertheless, the agent does appear to elicit the-
rapeutically relevant anticancer activity at the clinical level, and is
still under evaluation [69,70].
5. PU-H71 transcends prior attempts to optimize
purine-based heat shock protein 90 inhibitors
Although Chiosis and colleagues potentiated the development
of completely synthetic Hsp90 inhibitors, it was not until the
synthesis of PU-H71 (8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]-
9-[3-(propan-2-ylamino)propyl]purin-6-amine; Fig. 3A) that the
research group fully established thepotential of purine-based com-
pounds. Due to its iodide functional group, the positron emission
tomography (PET) radionuclide 124I can be inserted to produce the
imaging agent 124I-PU-H71. Conveniently, the PET agent is iden-
tical to PU-H71 in regards to activity, and its physical half-life of
4.02 days allows serial imaging for monitoring tumor PU-H71 con-
centrations for multiple days [18]. PU-H71 was initially reported in
a structure–activity relationship screening of multiple derivatives
designed to examine the effects of various substituents on anti-
Hsp90 activity [21]. Out of this comprehensive screening, PU-H71
demonstrated potent antineoplastic effects, while demonstrating
remarkable speciﬁcity toward transformed cells; binding afﬁnity
for Hsp90 from normal heart and lung tissues was 2-logs lower
than Hsp90 from SKBr3 human breast adenocarcinoma cells. This
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Fig. 3. Purine-based Hsp90 inhibitors. (A) Structures and molecular weights of PU3 and PU-H71. (B) PU-H71 differentiates between normal and oncogenic Hsp90. Although
PU-H71 has high afﬁnity for oncogenic Hsp90 at low concentrations, the agent needs to be administered at high to saturating concentrations to have marked inhibitory
activity against normal Hsp90. These observations form the rationale for administering PU-H71 at concentrations that will preferentially inhibit oncogenic Hsp90 used by
neoplastic cells to stabilize oncoprotein clients.
speciﬁcity translated into over 50-fold selectivity in inhibiting the
growth of malignant cells in comparison to normal ﬁbroblasts.
Further, no signiﬁcant cell death was observed in PU-H71 treated
MRC-5 human lung ﬁbroblasts even at the highest tested con-
centrations. The preferential activity of PU-H71 against cancerous
tissue under concentrations that do not perturb normal cells has
been conﬁrmed in multiple cell types (Fig. 3B) [71–73]. Since this
initial study, PU-H71 has been shown to be highly effective in vitro
and in vivo against several malignancies, each of which will be
brieﬂy highlighted to exemplify the potential PU-H71 has in cancer
chemotherapy.
5.1. Breast carcinoma
It has been long established that HER2/Neu overexpress-
ing breast carcinoma often relies on Hsp90, as the molecular
chaperone stabilizes its client oncoprotein, thereby maintaining a
large pool of active and folded oncoproteins that potentiate the
neoplastic phenotype [74–77]. Consequently, many of the Hsp90
inhibitors previously mentioned have been examined at the clin-
ical level as a novel chemotherapeutic intervention for HER2
positive breast carcinoma, with variable results being attained
[78,44,79,80]. In the initial study of PU-H71, the agent demon-
strated a very high propensity to initiate the degradation of HER2,
and subsequently was notably cytotoxic against malignant, but not
normal cells [21]. This alone made PU-H71 an exciting pharma-
ceutical prospect that warranted further preclinical investigation.
What made PU-H71 distinct from previous Hsp90 inhibitors is
that it also displayed potent in vitro and in vivo activity against
triple negative breast carcinoma (TNBC), a malignancy that does
not express the genes for estrogen receptor, progesterone receptor,
or HER2/Neu.
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Inprevious clinical studies, 17-AAG, IPI-504, and17-DMAGwere
all shown to be ineffective against TNBC tumors [81,82], suggesting
that Hsp90 inhibitors may have less relevance against this sub-
type of breast carcinoma. Although PU-H71 has not been formally
evaluated against TNBC at the clinical level, the agent has notable
preclinical antineoplastic activity against this subtypeof breast car-
cinoma that may warrant examination in afﬂicted patients. The
agent demonstrated that multiple human TNBC cell lines (MDA-
MB-468, MDA-MB-231, and HCC-1806) were markedly perturbed
by Hsp90 inhibition [83]. Further, multiple 75mg/kg i.p. doses
of PU-H71 induced complete responses and tumor regressions in
TNBCxenograftswithout toxicity to thehost, allowingTNBCtumors
to be treated with PU-H71 over several cycles that extended over 5
months. By contrast, 20 or 30mg/kg of 17-DMAG administered i.p.
daily for 3 days to tumor-bearing mice induced signiﬁcant weight
loss, diarrhea, and a high incidence of drug associated deaths (23%
of the population), in addition to being less efﬁcacious in regards to
antitumor activity [41,84]. More importantly, PU-H71 treatments
appeared to have sustainable antitumor activity, as no distinct evi-
dence of resistance or host toxicity were observed over this time
frame [83]. This potent activitywas attributed to PU-H71-mediated
downregulation of an assortment of known oncoproteins, includ-
ingEGFR, IGF1R (insulin-like growth factor 1 receptor), HER3, c-KIT,
and Raf-1 in addition toMAPK/ERK (MAPK;mitogen-activated pro-
tein kinasewas originally called ERK; extracellular signal-regulated
kinase) pathway components p-ERK2 and p90RSK that had not
previously been reported as Hsp90 clients. In addition, PU-H71
induced G2/M arrest in the TNBC cells, attributed to a notable
reduction in CDK1 (cyclin-dependent kinase 1) and Chk1 (check-
point kinase 1), and PU-H71 potentiated apoptosis through Akt
(also referred to as PKB; protein kinase B) and Bcl-xL downregu-
lation.
Interestingly, it also appeared that PU-H71 may have exerted
antineoplastic activity by decreasing the metastatic potential
of TNBC cells [83]. Although TNBC is not dependent on estro-
gen receptor, progesterone receptor or HER2 for maintaining
malignant characteristics, many cases of this subset of breast
carcinoma have elevated levels of nuclear factor B (NF-B),
potentiating enhanced cell survival by suppressing apoptosis,
induction of epithelial–mesenchymal transitions (EMT), resistance
to chemotherapy, and the invasive and metastatic propensity
of these tumors [85–87]. PU-H71 was shown to be in complex
with several critical components of the NF-B pathway, includ-
ing IRAK-1 (interleukin-1 receptor-associated kinase 1), Tab2/3
(TAK1-binding protein 2 and 3), and TBK1 (NAK/NF-B-activated
kinase). These interactions with the NF-B pathway are poten-
tially vital for exerting antitumor activity, as the IRAK/Tab complex
activates TAK1, which directly phosphorylates IKK at the acti-
vation loop to activate the IKK complex, resulting in NF-B
activation [88,89]. By inducing proteasome-mediated degrada-
tion of IRAK-1 and TBK1, 0.5 and 1M PU-H71 reduced NF-B
activity in MDA-MB-231 human breast carcinoma cells by ∼84%
and 90% respectively. Further, administration of PU-H71 sub-
stantially reduced Akt and ERK levels, which are both known
to promote the metastatic phenotype. By contrast, administra-
tion of geldanamycin or 17-AAG transiently promotes Akt and
ERK activation in breast carcinoma cells, an observation that has
attributed these Hsp90 inhibitors to potentially increasing the
metastatic potential of certain malignancies [90]. More impor-
tantly, PU-H71 demonstrated IC50 values 2–8 fold lower than
17-AAG against all examined TNBC cell lines, indicative of higher
in vitro cytotoxicity. Taken together, it appears that PU-H71 is
likely superior to geldanamycin-based Hsp90 inhibitors in the pre-
clinical treatment of TNBC, indicating that the agent may have
clinical potential against this aggressive breast carcinoma sub-
type.
5.2. Hematological malignancies
Hematological malignancies constitute a diverse constellation
of diseases linked by the transformation of normal blood compo-
nents into aberrantly proliferating neoplasms. Consequently, these
malignancies are characterized by a diverse assortment of aberrant
signaling cascades andoncoproteins.Despite this diversity, PU-H71
appears to be effective againstmany of these diseases,with efﬁcacy
being demonstrated againstmyeloproliferative neoplasms (MPNs),
lymphomas, and multiple myeloma.
5.3. Myeloproliferative neoplasms
MPNs refer to clonal hematological malignancies of the myeloid
lineage that are characterized by an elevated number of blood cells,
but lack many of the features of fully transformed cells, and have
yet to progress into a more aggressive stage, such as myelodys-
plastic syndrome (MDS) or acute myeloid leukemia (AML) [91,92].
These blood disorders include chronic myeloid leukemia (CML),
polycythemiavera (PV), essential thrombocytosis (ET), andprimary
myeloﬁbrosis (PMF). MPNs typically demonstrate characteristic
driver mutations, the two most notable being the BCR-ABL fusion
protein that constitutively activates the ABL1 tyrosine kinase, and
somatic activating mutations in JAK2 [31]. Interestingly, PU-H71
demonstrates high afﬁnity for Hsp90s in K562 human CML cells
that contain the oncogenic BCR-ABL fusion protein, but not the
wild type ABL tyrosine kinase [31]. However, the Hsp90-targeting
mAB H9010 indiscriminately binds Hsp90, regardless of whether
it contains BCR-ABL or ABL1. These data suggest the existence of
distinct pools of Hsp90 that are preferentially bound to either BCR-
ABL or ABL1 in CML cells [31]. It also suggests that PU-H71 can
speciﬁcally target Hsp90s engaged in oncogenic activity, an obser-
vation with basic research and clinical implications. By contrast,
synthetic Hsp90 inhibitors SNX-2112 and NVP-AUY922, as well as
geldanamycinwere less effective at isolatingHsp90s bound to BCR-
ABL, with NVP-AUY922 showing activity very similar to H9010.
The study also indicated that PU-H71 could be used as a molec-
ular probe to uncover novel carcinogenic mechanisms in CML and
potentially other neoplasms, as the agent was used in combination
with afﬁnity based proteomics to uncover a new STAT activa-
tion mechanism that was not previously characterized [31]. Future
studies will hopefully produce novel targets and/or concomitant
chemotherapeutic strategies to increase the overall efﬁcacy of var-
ious treatment protocols.
Although PU-H71 may have potential as a chemotherapeu-
tic agent against BCR-ABL driven hematological malignancies
(Philadelphia chromosome positive CML and Philadelphia chromo-
some positive acute lymphoid leukemia; ALL), TKIs have already
demonstrated commendable efﬁcacy against such neoplasms.
Therefore, PU-H71 may have greater utility against MPNs that
are characterized by Janus kinase-signal transducer and activa-
tor of transcription (JAK-STAT) driver mutations, which have been
less successfully targeted by JAK inhibitors. As demonstrated in
numerous studies, tumorigenic versions of JAK2 appear to be a
faithful client of Hsp90 [14,93–95], suggesting that PU-H71 may
be a novel therapeutic modality by which to disrupt oncogenic
JAK-STAT signaling. Indeed, it has been demonstrated that the
Hsp90 inhibitor potentiates a lower IC50 value against cell lines
bearing mutations that result in constitutive activation of the
JAK-STAT signaling pathway (JAK2V617F and MPLW515L) in com-
parison to Philadelphia chromosome positive cell lines (Ba/F3
murine interleukin-3 dependent pro-B and KU812 chronicmyeloid
leukemia cells) and JAK2 wild type THP1 human acute mono-
cytic leukemia cells [96]. Further, PU-H71 appears to preferentially
perturb neoplastic cell signaling, as the agent potently inhibited
STAT5 phosphorylation inMPNpatient samples, but not cord blood
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samples, consistent with JAK2-dependent signaling by MPN cells
[96]. In addition, PU-H71 inhibited mutant-associated erythrocy-
tosis and megakaryopoiesis in JAK2V617F and MPLW515L murine
models, without affecting normal erythrocytosis and megakary-
opoiesis.
Perhaps the most striking observations conﬁrming the poten-
tial efﬁcacy of PU-H71 as a therapeutic intervention of MPN has
come from the direct analysis of its antineoplastic activity in vivo.
In multiple studies, administration of PU-H71 i.p. in MPN-bearing
mice has potentiated long term survival at exceptionally high
rates [96–98]. Notably, the PU-H71 doses required to inhibit MPN
colony formation are well below the 2–4M that can be achieved
in vivo, as is consistent with the potent inhibition of cell via-
bility at feasible drug concentrations [98]. Interestingly, PU-H71
may be more effective at inhibiting JAK-STAT signaling than JAK
inhibitors, as treatment with PU-H71 elicited increased inhibition
of JAK-STAT signaling, reduced disease burden, and improved sur-
vival in comparison to ruxolitinib [98]. Further, PU-H71 appears
to synergize with JAK inhibitors, as concomitant administration
of PU-H71 and ruxolitinib reduced total and phospho-JAK2 and
achieved more potent inhibition of downstream signaling than
PU-H71 or ruxolitinib monotherapy [97]. Concomitant adminis-
tration also improved blood counts, spleen weights, and reduced
bone marrow ﬁbrosis compared with the monotherapies without
attendant increases in toxicity. Therefore, PU-H71/JAK inhibitor
treatment protocols are an attractive prospect for MPN patients
thatwarrants further investigation. These ﬁndingsmay also extend
to certain forms of ALL, which can express activating mutations in
JAK2 [99,100], particularly in subsets of patients with high-risk ALL
[101,102]. In addition, in vitro and in vivo studies have indicated
that many solid tumors, including carcinomas of the breast, lung,
and prostate activate the JAK-STAT pathway through autocrine and
paracrinemechanisms [103], suggesting thatHsp90 inhibitionmay
portend a therapeutic beneﬁt in these malignancies.
5.4. Lymphomas
Lymphomas are a highly heterogeneous subset of solid tumors
that are composedofneoplasticBorTcells.While some lymphomas
such as classical Hodgkin’s lymphoma respond well to current
therapeutic strategies, there are many types that respond poorly
to currently available chemotherapy or radiotherapy [104,105].
Diffuse large B cell lymphoma (DLBCL) is the most common non-
Hodgkin’s lymphoma found in adults, and currently has a ﬁve year
survival rate of 58–67% in these older patients; pediatric DLBCL has
a ﬁve year survival rate ranging from 70 to 90% [106]. The malig-
nancy is therefore a manageable, but still problematic occurrence
in the clinical setting. DLBCL is characterized by mutations in the
Bcl6 (B-cell lymphoma) transcriptional repressor,which is themost
frequently involved oncoprotein observed (∼40% of all cases are
marked by constitutive Bcl6 expression, while ∼70% are Bcl6 pos-
itive) [107,108]. Bcl6 directly represses critical tumor suppressors
ATR (Ataxia telangiectasia and Rad3-related) and TP53 (tumor pro-
tein p53) [109]. However, it has also beendemonstrated thatHsp90
is frequently expressed in primary DLBCL [109,110], indicative of a
potential link between Bcl6 stability andHsp90 expression. Indeed,
Bcl6 has been conﬁrmed as a client protein of Hsp90, and conse-
quently is highly susceptible to PU-H71 [111,112]. In vivo, PU-H71
signiﬁcantly prolonged the survival of Bcl6-dependent tumor-
bearing mice, but not Bcl6-independent DLBCL Toledo xenografts
at comparable doses [111]. Important for potential clinical applica-
tions, PU-H71 was preferentially retained in DLBCLs compared to
normal tissues at pharmacologically relevant concentrations at all
timepoints examined. Further, PU-H71 facilitated the upregulation
of Bcl6 target genes involved in DNA damage checkpoints [113],
suggesting that the agent may sensitize certain DLBCL tumors to
the cytotoxic effects of chemotherapeutic agents currently used at
the clinical level. This potential therapeutic strategy may be sup-
plemented with RI-BPI, a retro-inverted Bcl6 peptide inhibitor that
induces the expression of p300 (p300 lysine acetyltransferase) and
BAT3, which potentiate cell death in DLBCL cell lines [113]. Con-
comitant administration of RI-BPI and PU-H71 was remarkably
potent against DLBCL xenografts, with 50% of mice treated with
both agents having no evidence of tumor when their matched con-
trols were sacriﬁced due to complications from the tumor burden.
In addition to DLBCL, PU-H71 has shown efﬁcacy against lym-
phoma cells infected by Epstein–Barr virus (EBV) or Kaposi’s
sarcoma associated herpes virus (KSHV) [114]. Speciﬁcally, viral
and cellular proteins identiﬁed as Hsp90 clients were signiﬁ-
cantly downregulated, including many involved in NF-B signaling
(particularly the oncogenic vFLIP-IKK signaling complex that pro-
motes KSHV carcinogenesis [115,116]), apoptosis, and autophagy.
These in vitro effects were validated by potent in vivo activity
against BC3 primary effusion lymphoma, a cancer cell line in which
KSHV is the etiologic agent. Sincemanyapoptosis pathwayproteins
in BC3 cells bound toHsp90, PU-H71was used in combinationwith
the pan-BCL2 inhibitor obatoclax to assess their potential in vitro
synergy. The agents subsequently demonstrated dramatic synergy,
and may be indicative of a therapeutic combination that warrants
further preclinical investigation.
5.5. Multiple myeloma
Multiple myeloma is a cancer of the antibody producing plasma
cells in which collections of abnormal plasma cells accumu-
late in the bone marrow, interfering with hematopoiesis. Novel
agents such as proteasome inhibitors (bortezomib and carﬁlzomib
[117]) and immunomodulatory/antiangiogenic drugs (thalido-
mide, lenalidomide, and pomalidomide [118]) have increased
progression free and overall long term survival, but the malig-
nancy is still designated as incurable and the ﬁve year survival
rate remains at ∼45% [119]. As indicated by the efﬁcacy of PU-H71
against multiple myeloma cells [120], Hsp90 is an attractive tar-
get for further preclinical evaluation. Several human myeloma cell
lines including those that are resistant to corticosteroids and borte-
zomib are highly sensitive to PU-H71 [120]. The Hsp90 inhibitor
activated the unfolded protein response by initiating a blockade
of gp96 (the Hsp90 paralog found in the endoplasmic reticu-
lum), as well as induced cell cycle arrest at the G1-S checkpoint
and potentiated caspase-dependent apoptosis. Interestingly, a sta-
ble gp96 knockdown human myeloma cell line was found to be
more resistant to PU-H71 and other Hsp90 inhibitors (17-AAG and
17-DMAG) even though these cells were more sensitive to conven-
tional chemotherapy employed againstmultiplemyeloma. PU-H71
also demonstrated notable synergistic interactions with borte-
zomib, dexamethasone, melphalan, and thalidomide, suggesting
that the Hsp90 inhibitor could be used to supplement current anti-
myeloma treatment protocols.
5.6. Ewing’s sarcoma
As shown in vitro against multiple myeloma, notable syner-
gism may exist between PU-H71 and bortezomib. Being a potent
inhibitor of the 26S proteasome, bortezomib prevents proteasome-
mediated degradation of ubiquitinated proteins that may be vital
for promoting apoptosis in malignant cells, and also assists in their
activation. Supporting this notion are data that indicate the pro-
teasome inhibitor induces G2/M cell cycle arrest and apoptosis by
causing pro-apoptotic Bcl-2 phosphorylation and cleavage [121].
Interestingly, one of the most notable mechanisms of PU-H71 is
indirect degradation of Hsp90 oncoclient proteins via the ubiqui-
tin/proteasome system [39]. Although these two mechanisms of
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action may at ﬁrst appear to be conﬂicting, the synergy between
PU-H71 and bortezomib is apparent, and has been reproduced
in vitro and in vivo against Ewing’s sarcoma [122], a predomi-
nately pediatric bone cancer characterized by small, round, and
blue cells that are associated with highly undifferentiated malig-
nancies [123].
PU-H71 potentiated a signiﬁcant therapeutic window when its
effects against multiple Ewing’s sarcoma cell lines (A673, CADO-
ES-1, RD-ES, SK-ES-1, SK-PN-DW, and TC71) were compared to
normal and/or benign cells (HS-5 human bone marrow mesenchy-
mal stromal cells, sarcomaderivedbenignmesenchymal stemcells,
and human brain vascular pericytes) [124], again conﬁrming the
preferential activity of the Hsp90 inhibitor. As described in other
cancer types [83,124–126], PU-H71 also potentiated G2/M arrest,
anddepletedHsp90 client proteins AKT, pERK, RAF-1, c-MYC, c-KIT,
IGF1R, hTERT (human telomerase reverse transcriptase) and EWS-
FLI1 (Ewing’s sarcoma-Friend leukemia integration 1 transcription
factor). In regards to potential drug synergy with bortezomib, Fa-
CI (fraction affected-combination index) plots and isobolographic
analyses conﬁrmed synergism between PU-H71 and bortezomib.
More importantly, Ewing’s sarcoma xenograft-bearing mice fared
much better when treated with the combination compared to
the vehicle or either agent alone, providing a compelling ratio-
nale for further preclinical and the eventual clinical evaluation
of PU-H71/bortezomib treatment protocols. The noted synergism
between PU-H71 and bortezomib was attributed to the accu-
mulation of ubiquitinated proteins that is potentiated by both
agents, ultimately resulting in highly cytotoxic proteotoxic stress
in affected cancer cells.
5.7. Hepatocellular carcinoma
Chemotherapeutic intervention against hepatocellular carci-
noma has been historically difﬁcult, as many traditional broad
ranging cytotoxic agents are ineffective in patients afﬂicted with
these malignancies [127]. Recent advances in molecular-based
chemotherapy have yielded slight improvements in prognosis, as
the versatile TKI sorafenib has shown efﬁcacy in select individuals
[128,129]. Nevertheless, unresectable hepatocellular carcinoma
typically portends a survival of less than 6 months post-diagnosis,
although some patients fare much better [129]. Hsp90 inhibitors
have not been extensively examined for their antitumor activity
against this malignancy because geldanamycin-based analogs are
known to induce dose-limiting liver toxicity (refer to section Initial
Attempts to Target Heat Shock Protein 90 Using Semisynthetic Deriva-
tives of Natural Products), which would further damage an organ
already partially compromised from malignant progression. How-
ever, PU-H71 does not contain the benzoquinone moiety that has
been linked to liver toxicity, thereby suggesting that the agent may
yield some therapeutic beneﬁt.
In the carcinogenesis of hepatocellular carcinoma, Hsp90 is
vital for maintaining the malignant phenotype, as the pro-
tein promotes the aberrant expression and activity of crucial
hepatocarcinogenesis-driving factors (IGF1R, HGFR; hepatocyte
growth factor receptor, Akt, CRAF, and CDK4) [124,130]. PU-H71
was shown to potently inhibit the expression of these proteins,
and caused G2/M arrest, as well as apoptosis [124]. Normal hepa-
tocytes were exposed to these inhibitory concentrations, with
little apparent toxicity observed. Perhaps most important was the
fact that PU-H71 was retained in xenograft tumors at pharma-
cologically relevant concentrations, while being rapidly cleared
from non-tumorous liver. Consequently, PU-H71 showed potent
and prolonged in vivo Hsp90 inhibitory activity and reduced
tumor growth without causing the liver toxicity that is asso-
ciated with geldanamycin-based Hsp90 inhibitors. These data
suggest that hepatocellular carcinomas may be responsive to
PU-H71-mediated Hsp90 inhibition, warranting further preclinical
investigation.
5.8. Lung carcinoma
Despite public awareness campaigns and novel molecular tar-
geting therapies, lung carcinoma remains the most common cause
of cancer-related death in men and women in the world, with
approximately 14 million new cases and 8.2 million cancer related
deaths reported in 2012 [131]. A particularly aggressive subtype
of lung carcinoma is small cell lung carcinoma (SCLC), a poorly
differentiated neuroendocrine tumor that is marked by the same
small-blue-round-cell tumors found in Ewing’s sarcoma [132].
Unlike other forms of lung carcinoma, there has yet to be a clearly
deﬁned molecular target that responds well to currently approved
mABsor TKIs. AlthoughSCLC is notably sensitive to traditional cyto-
toxic chemotherapy, the malignancy quickly develops resistance,
signiﬁcantly limiting the treatment options available to patients
[132]. Therefore, characterizing molecular oncogenic targets in
SCLC that are particularly susceptible to drug inhibitionwould be of
monumental importance in the clinical management of this malig-
nancy.
Lo and behold, SCLC may be vulnerable to Hsp90 inhibition,
as demonstrated by PU-H71 [133]. Unlike other cancers, SCLC
does not have a functional death receptor pathway [134,135],
suggesting that apoptosis is predominately mediated through the
intrinsic, mitochondrial associated pathway. Apoptotic signaling
in mitochondria leads to membrane depolarization, resulting in
activation of the effector caspase-3, poly(ADP-ribose) polymerase
(PARP) cleavage, and DNA fragmentation. PU-H71, as well as other
purine-based inhibitors considerably upregulated caspase-3 and
caspase-7 activity and potentiated the dissolution ofmitochondrial
membrane potential [133], collectively indicating that Hsp90 inhi-
bition can inducemitochondrial-mediated apoptosis in SCLC. Using
thepurine-based inhibitors asmolecular probes, itwas later uncov-
ered that pharmacological inhibition of Hsp90s in SCLC cells frees
Apaf-1 (apoptotic protease activating factor 1) to form an Apaf-1-
caspase-9 complex [133]. This complex elicits apoptotic signaling
after cytochrome c is released, which is triggered by Akt inac-
tivation and subsequent BAD (Bcl-2-associated death promoter)
dephosphorylation. Therefore, it appears thatHsp90 regulates apo-
ptosis in SCLC by acting as a negative regulator of Apaf-1 and by
controlling the PI3K-Akt survival pathway.
These effects on apoptotic signaling appear to potentiate cell
death in both drug sensitive and multidrug resistant SCLC cells in
vitro (including H69AR, SKI-AC3 and WBA), as PU-H71 and its con-
gener PU-H58 inhibited Hsp90 and caused substantial death in all
tested cell lines [133]. The marked antineoplastic activity against
SKI-AC3 is particularly noteworthy, as the primary SCLC cell line
was harvested from the malignant pleural effusion of a patient
whohad recurrent disease after being treatedwith cisplatin, etopo-
side, topotecan, gemcitabine, and whole-brain radiotherapy and
had extensive metastases in the lungs, liver, lymph nodes, subcu-
taneous tissue, left adrenal gland, and brain. This prominent in vitro
activity of PU-H71 was matched by its in vivo effects; in NCI-N417
xenografts, Akt inactivation and cleavage of PARP was detected as
early as 6h after PU-H71 administration, and the effects were still
evident at 36h. These effects occurred at pharmacologically rele-
vant doses of PU-H71 that were retained in tumors, and signiﬁcant
tumor growth inhibition was noted at the time of termination. The
study also likely documented the ﬁrst instance of apoptosis in vivo
mediated by a Hsp90 inhibitor, indicative of the potential PU-H71
and other agents of this class may have against SCLC. It should
be cautioned that since several currently approved chemothera-
peutic agents can elicit initial dramatic responses in SCLC, much
more extensive preclinical in vivo investigation is needed to
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conﬁrm the notable antitumor activity PU-H71 demonstrated in
the study.
5.9. Thymic epithelial tumors
Thymic epithelial tumors constitute a diverse array of cancers
originating from the thymus, the site of T-lymphocyte maturation.
As such,malignancies of the thymus can be classiﬁed into twomain
groups; thymomas that contain immature non-malignant lym-
phocytes and the epithelial component retains histologic features
speciﬁc to the normal thymus, and thymic carcinomas that exhibit
a set of histologic features that are similar to those found in carcino-
mas of other organs, rather than a normal thymus [136–138]. These
malignancies are uncommonandhave a variable prognosis, as indi-
cated by a comprehensive study of 1320 Japanese patients inwhich
the ﬁve year survival rate was 67% for patients treated with total
resection, 30% for patients treated with subtotal resection, and 24%
for patients whose disease was inoperable [136]. Being a fairly rare
cancer, the underlying molecular mechanisms of thymic epithe-
lial tumors have been inadequately described, resulting in a dearth
of available efﬁcacious targeted therapies. Nevertheless, a recent
study has suggested Hsp90 inhibition via the administration of PU-
H71 may potentiate novel molecular-based therapeutic strategies
in these malignancies [125].
As is the case with more prevalent cancers, thymic epithelial
tumors of both the thymoma and thymic carcinoma classiﬁca-
tion rely on oncoproteins that are clients of Hsp90 [125]. Hsp90
inhibition signiﬁcantly reduced the viability of thymoma (T1682)
and thymic carcinoma (TC1889) cells, induced cell cycle arrest
and apoptosis, and blocked invasiveness. PU-H71-mediated Hsp90
inhibition triggered the degradation of multiple oncogenic clients,
including IGF1R, CDK4, and the inactivation of PI3K/Akt and
RAF/Erk signaling. In addition, the use of PU-H71 as a molecular
probe revealed that the IGF/IGF1R signaling axis contributed to the
establishment of the anti-apoptotic phenotype of thymic epithelial
tumors, with IGF1R being overexpressed in advanced malignancies
derived from patient tumor samples. These data ultimately suggest
that Hsp90 inhibition may be a viable therapeutic strategy in this
uncommon neoplasm, but the assertion will need to be validated
by in vivo examination.
6. Potential combination with Hsp70 inhibitors
As has been demonstrated in this review, Hsp90 is a viable
antineoplastic target that can be effectively inhibited by PU-H71,
as well as many other compounds. As a compensatory mech-
anism, many cancer cell lines increase expression of Hsp70,
another molecular chaperone that is responsible for an assortment
of physiological functions, including the regulation of apoptotic
machinery (apoptosome, the caspase activation complex, and AIF;
apoptosis-inducing factor) and have a similar role as Hsp90 in the
proteasome-mediated degradation of apoptosis-regulating pro-
teins. Further, Hsp70 is involved in carcinogenesis, as suggested
by their constituency in the Hsp90 super-chaperone machinery,
being associated with the Hsp90:HOP:Hsp70 complex responsible
for stabilizing numerous oncoproteins [139–142]. Although inhibi-
tion of Hsp90 can potentiate potent antitumor activity, the effects
canpotentiallybecircumventedby theactivityofHSF-1 (heat shock
factor-1), the master regulator of the heat shock response, and the
subsequent effects of Hsp70. HSF-1 is another Hsp90 client, but
unlike oncoproteins, it becomes activated when Hsp90 is inhibited
[143]. Activation of HSF-1 results in a feedback increase in Hsp70
levels, and due to the anti-apoptotic functionality of Hsp70 that
inhibits both intrinsic and extrinsic apoptotic pathways, the feed-
back response limits the potency of Hsp90 inhibitors. Indeed, the
anti-apoptotic function of Hsp70 is not limited to Hsp90 inhi-
bition, and Hsp70 protects cells from many other apoptotic and
necrotic stimuli [142,143]. Therefore, the concomitant inhibition
of Hsp90 and Hsp70 could be particularly cytotoxic for malignant
cells dependent on oncogenic addiction.
Unfortunately, it has been much more difﬁcult to develop
effective Hsp70 inhibitors. As with Hsp90, the protein contains
an N-terminal ATPase domain, as well as a C-terminal client
protein-binding domain that creates a ligand activated, bidirec-
tional molecular switch. However, Hsp70 has a notably strong
afﬁnity for ADP and due to the high intracellular concentrations
of ATP that are typically present [144,145], designing an agent that
would be capable of competitive inhibition under these circum-
stances is particularly challenging. In addition, the binding mode
of ATP to Hsp70 is such that important polar interactions are made
with its - and -phosphate groups that lie buried within a polar
cavity of the protein [145]. Attempts to mimic these interactions
have resulted in highly polar, but unwieldable molecules that have
potent afﬁnity for the ATP pocket, but possess minimal cellular
activity [146].
Since inhibition of the ATPase activity in Hsp70 does not appear
to be a viable therapeutic prospect as it is with Hsp90, potentially
novel drug responsive targets need to be examined. A particularly
interesting approach has been taken by the Chiosis laboratory,
the same group that developed the ﬁrst completely synthetic
Hsp90 inhibitor. Since insufﬁcient crystalline information had
been acquired for human Hsp70 in an open, active conforma-
tion, Chiosis et al. used homology modeling to characterize a
theoretical full-length human Hsp70 that captured the confor-
mational ﬂexibility of the protein [144]. These conformational
analyses revealed another pocket, located near the N-terminus
that was not evident nor entirely predicted by the available
crystal structures of Hsp70. Chiosis et al. subsequently synthesized
YK5 (N-(6-amino-2-(4,6-dimethoxy-2-(4-methylpiperazin-1-yl)-
pyrimidin-5-ylthio)pyrimidin-4-yl)acrylamide), a novel 2,5′-
thiodipyrimidine and 5-(phenylthio)-pyrimidine compound that
bound to the allosteric site, and subsequently perturbed cancer
viability through a Hsp70-mediated mechanism (Fig. 4A) [144].
Using YK5 as a model, other agents with closely related struc-
tures were developed to optimize Hsp70 inhibition, and have
shown notable antineoplastic potential against multiple cancer
cell lines (Kasumi-1, MDAMB-468, Mia-PaCa-2, MOLM-13, and
SKBr3) in vitro [147,148]. These congeners contain either an
acrylamide moiety that reacts with a cysteine residue in the
allosteric pocket once the molecule inserts into the binding site,
or are functionalized at key positions along the carbon skeleton
to elicit non-covalent interactions that together potentiate a
binding afﬁnity that is comparable to the inhibitory potential of
the acrylamide-based agents (Fig. 4B). If the notable in vitro activity
of these agents can be reproduced in vivo, potential therapeutic
approaches involving the concomitant inhibition of Hsp90 and
Hsp70 as a strategy by which to limit Hsp90 inhibitor resistance
would be a sensible prospect warranting preclinical investigation.
7. Other potential concomitant therapeutic approaches
Already, PU-H71 has demonstrated notable synergistic activ-
ity with bortezomib in preclinical models of multiple myeloma
and Ewing’s sarcoma [120,122]. There is an ever expanding
ﬁeld of proteasome inhibitors currently available to investigate
other potential synergistic combinations, including carﬁlzomib, a
semisynthetic analog of the natural product epoxomicin (isolated
from Actinomycetales bacteria [149]) that irreversibly binds the
20S proteasome, potentiating a cytotoxic increase in polyubiqui-
tinated proteins associated with cell cycle arrest, apoptosis, and
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Fig. 4. InteractionofHsp90:HOP:Hsp70 complexwithoncogenic proteins, and its inhibitionusing smallmolecule inhibitors. (A)Onco-client proteins areprocessed throughan
intermediate complex containing Hsp90, Hsp70, and HOP, potentiating the conformational maturation of the oncoprotein, thereby promoting cell proliferation and survival.
YK5 (molecular structure shown) is a 2,5′-thiodipyrimidine that interferes with the formation of a competent chaperone/onco-client complex, resulting in oncoprotein
destabilization. Subsequent proteasome degradation of the oncoprotein elicits growth arrest, and potentially cell death via apoptosis. (B) Optimizing the inhibitory activity of
2,5′-thiodipyrimidines. Irreversible Hsp70 inhibitors of this drug class have an electrophilic acrylamide moiety that reacts with Cys267 of Hsp70 once the molecule conforms
to a pocket located at the N terminal domain. Reversible inhibitors increase the already notable enthalpy of the appropriate ﬁt by modifying key functional groups along
the carbon skeleton to increase non-covalent interactions. This includes replacing the electrophilic acrylamide moiety with a functional group capable of forming an ionic
bridge and ﬁlling the hydrophobic pocket occupied by an ethoxy group in 1 with a benzyloxy group. These modiﬁcations result in ligands with a reversible mode of binding
that have comparable potencies to irreversible inhibitors. 1: N-(6-amino-2-((4,6-diethoxy-2-(4-methylpiperazin-1-yl)-pyrimidin-5yl)thio)pyrimidin-4-yl)acrylamide. 2: 2-
amino-N-(3-((4-(benzyloxy)-2-(4-methylpiperazin-1-yl)-pyrimidin-5-yl)thio)phenyl)acetamide. Important functional moieties are highlighted with color coded outlines;
blue (acrylamide moiety) and red (benzyloxy moiety).
Source: Data in panel B were acquired from [147]. (For interpretation of the references to color in this legend, the reader is referred to the web version of the article.)
the inhibition of neoplastic growth [150]. Carﬁlzomib was FDA
approved in 2012 for patientswithmultiplemyeloma that is refrac-
tory or has developed resistance to at least two prior therapies,
including treatment with bortezomib and an immunomodula-
tory agent. Therefore, concomitant administration of PU-H71
and carﬁlzomib in addition to other chemotherapeutic agents
may be a novel approach to generate longer, more durable
responses in this currently incurable malignancy. Supporting this
notion is the observation that PU-H71 also demonstrates syner-
gism in vitro with dexamethasone, melphalan, and thalidomide,
other agents currently used as standard therapy for multiple
myeloma [120].
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HER2/Neu overexpressing breast carcinomas and gastric adeno-
carcinomas also appear to be malignancies potentially susceptible
to PU-H71-mediated drug synergism, as the oncoprotein is a faith-
ful client of Hsp90. Indeed, other Hsp90 inhibitors have been tested
in this regard with trastuzumab, with positive responses being
observed. These studies should be extended to other agents indi-
cated for HER2 malignancies, including pertuzumab (a mAB that
binds a different epitope than trastuzumab), the antibody–drug
conjugate (ADC) trastuzumab emtansine, and lapatinib, along with
other potential TKIs. The concept of using PU-H71 and other Hsp90
inhibitors in combination with agents directed against speciﬁc
oncoproteins that areHsp90clients is indeedanattractiveprospect,
and could be investigated in many different cancers. Agents of
potential interest include, but arenot limited to inhibitors of the fol-
lowing proteins; ALK, BCR-ABL, BRAF, HER2, JAK2, KIT, and mTOR.
In addition to its efﬁcacy against HER2 positive breast carci-
noma, PU-H71has shownnotable activity against TNBC [83]. Breast
carcinomas of this subtype are typically treated with standard
cytotoxic chemotherapy, including microtubule-directed mitotic
inhibitors [151]. The fact that PU-H71 markedly increases the pro-
portion of cells at G2/M, suggests that it could be combined with
mitotic inhibitors such as vinca alkaloids, taxanes, epothilones, and
eribulin to increase their antitumor activity. Clinical studies inves-
tigating the potential of Hsp90 and mitotic inhibitors have been
previously described [39,63–65], and such studies involving PU-
H71 are warranted.
Finally, a potentially novel concomitant chemotherapeutic
strategy that could be explored at the preclinical level would be
the combination of PU-H71 with microﬁlament-directed agents.
Although there are no microﬁlament-directed agents currently
approved by the FDA or other pharmaceutical regulating bodies,
these compounds have intriguing therapeutic potential. Antineo-
plastic mechanisms of these agents include the potentiation of
multinucleated cancer cells that are exquisitely sensitive to other
forms of chemotherapy via inhibition of cytokinesis, reducing
metastatic potential by limiting cell motility and adhesion (as well
as inhibiting the secretion of glucosaminidases), and binding ATP-
binding cassette (ABC) transporters, thereby enhancing the activity
of other chemotherapeutic agents [1,152,153]. Due to their unique
mechanisms of action, microﬁlament-directed agents have been
shown to sensitize malignant cells to mTOR inhibitors, nucleic
acid-directed agents and microtubule-directed agents [154–158].
These are some of the very agents that PU-H71may synergizewith,
indicating that drug synergy may exist between Hsp90 inhibitors
and microﬁlament-directed agents. This is supported by the G2/M
cell cycle arrest activity observed after Hsp90 inhibition, as con-
comitant inhibition of mitosis at this critical checkpoint and at
cytokinesis would likely reduce the ability of malignant cells
to carry out a successful mitotic event. Several microﬁlament-
directed agents of particular interest include cytochalasins and
closely related chaetoglobosins, latrunculins, and jasplakinolide,
each ofwhichhas been comprehensively described in prior reviews
[1,152,159]. Although the synergismbetweenHsp90 inhibitors and
microﬁlament-directed agents is purely theoretical at this point,
preclinical investigation of this concomitant approach could vali-
date potentially novel therapeutic strategies.
8. Conclusion
In an era of precision medicine that has enabled clinicians
to select optimal therapies based on the genetic proﬁle or other
molecular/cellular analyses of the patient’s tumor, the chaperome
provides a novel target by which to preferentially damage neoplas-
tic cells. Proteins that constitute this unique molecular family are
vital to the carcinogenesis of many malignancies, and provide a
method by which to inhibit speciﬁc oncoproteins without the use
of mABs or TKIs. The molecular chaperone that has shown the most
therapeutic potential, Hsp90, can be successfully targeted through
the use of compounds that potently inhibit its ATPase function-
ality. However, preliminary attempts to target Hsp90-dependent
tumors in the clinical setting with derivatives of natural products
have so far been unsuccessful due to their unfavorable pharma-
cokinetic properties and toxicity proﬁles. While second generation
natural product analogs have shown potential, it may be necessary
to develop completely synthetic small molecule inhibitors that do
not rely on the key functional groups of geldanamycin or radicicol.
Purine-based inhibitors were the ﬁrst class of fully synthetic
anti-Hsp90 agents developed, and have been useful in probing the
oncogenic function of Hsp90 due to their remarkable speciﬁcity
for the protein. One congener in particular, PU-H71, has shown
notable preclinical antineoplastic activity in a variety of cancer
types, and is now being examined at the clinical level. Unlike some
of its predecessors, PU-H71 has demonstrated marked speciﬁcity
for malignant cells, displaying minimal toxicity to normal tissue.
Further, the agent has the added beneﬁt of having a replaceable
iodide functional group, enabling the PET radionuclide 124I to be
inserted for clinical pharmacological examination. Perhaps most
importantly is the ability of PU-H71 to synergize with a variety
of currently approved chemotherapeutic agents, suggesting the
Hsp90 inhibitor could be used to supplement current treatment
protocols.
Nevertheless, PU-H71 is only in the initial stages of clinical
examination and its potential as a pharmaceutical drug remains
uncertain. Targeting Hsp90 and other molecular chaperones is a
fairly novel therapeutic strategy, and it will likely be years before
an inhibitor of this class is clinically validated. Potential dual inhi-
bition of the Hsp90:HOP:Hsp70 complex via Hsp90 and Hsp70
inhibitors is apotentially excitingprospect, butwill need tobe thor-
oughly examined in preclinical models before it can meet clinical
scrutiny. The potential payoff is immense, as it has been elucidated
that the expression of molecular chaperones is inherently differ-
ent in normal and malignant cells, providing a rational approach
to indirectly target oncoproteins and aberrant signaling cascades.
Critical assessment of these novel antineoplastic agents will hope-
fully potentiate a new avenue of cancer therapy, and increase the
rate at which sustainable remissions are seen in a select group of
malignancies.
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